Nina Devlin

facebook_page
twitter_page

Last quote by Nina Devlin

Mylan received an information request from the FTC months ago as part of a preliminary investigation. Any suggestion that Mylan took any inappropriate or unlawful actions to prevent generic competition is without merit. We note that the epinephrine auto-injector market is and always has been competitive, with multiple products competing on the market since we acquired EpiPen Auto-Injector. Further, Teva has had patent licenses to launch their proposed generic alternative to EpiPen Auto-Injector since June 2015, pending FDA approval, years prior to patent expiry.
Jan 30 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Nina Devlin is associated, including Mylan and Tricare. Most recently, Nina Devlin has been quoted saying: β€œIt was always our intention that the reclassification would benefit all government agencies impacted by the classification, including the VA and Tricare (Defense) programs.” in the article EpiPen price hikes add millions to Pentagon costs. An other article where Nina Devlin has been quoted is New York attorney general investigates EpiPen manufacturer.
Automatically powered byStoryzy

Quotes by Nina Devlin

<
facebook_page
twitter_page
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided